Includes whereas clauses.
Amends GS 90-81.82, concerning informed consent to abortion under the Woman's Right to Know Act, to require the following additional information be provided to a woman before a medical abortion. Requires that, immediately prior to administering the drug Mifepristone, the physician or qualified health professional must inform the woman that both (1) it is possible to discontinue a drug-induced abortion by not taking the Mifepristone and taking progesterone to reverse the effects of the Mifespristone and (2) information on how, where, and from whom women can obtain assistance in discontinuing a medical abortion is available on the Department of Health and Human Services' website. Further, immediately prior to administering the drug Misoprostol, requires the physician or qualified professional to provide medical proof to the woman that fetal death has occurred. Amends GS 90-21.84 to require DHHS to include the above information relating to the drug Mifepristone, as required in new GS 90-21.82(2a)a, on its website. Effective October 1, 2019.
Directs DHHS to update its website to provide information on how, where, and from whom women can obtain assistance in discontinuing the drug-induced abortion process on or before July 1, 2019.
|View NCGA Bill Details||2019-2020 Session|
AN ACT DIRECTING THAT CERTAIN INFORMATION BE PROVIDED TO WOMEN CONSIDERING A MEDICAL ABORTION IN ORDER TO SATISFY INFORMED CONSENT REQUIREMENTS; AND REQUIRING THE DEPARTMENT OF HEALTH AND HUMAN SERVICES TO MAKE THAT INFORMATION AVAILABLE ON ITS INTERNET WEB SITE.Intro. by Pittman.
Status: Ref to the Com on Judiciary, if favorable, Health, if favorable, Rules, Calendar, and Operations of the House (House action) (Feb 6 2019)
Bill H 22 (2019-2020)Summary date: Feb 5 2019 - More information